Matteo Molica

1.5k total citations
70 papers, 773 citations indexed

About

Matteo Molica is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Matteo Molica has authored 70 papers receiving a total of 773 indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Hematology, 42 papers in Genetics and 18 papers in Molecular Biology. Recurrent topics in Matteo Molica's work include Chronic Myeloid Leukemia Treatments (36 papers), Chronic Lymphocytic Leukemia Research (30 papers) and Acute Myeloid Leukemia Research (27 papers). Matteo Molica is often cited by papers focused on Chronic Myeloid Leukemia Treatments (36 papers), Chronic Lymphocytic Leukemia Research (30 papers) and Acute Myeloid Leukemia Research (27 papers). Matteo Molica collaborates with scholars based in Italy, United States and India. Matteo Molica's co-authors include Massimo Breccia, Fulvio Massaro, Giuliana Alimena, Paolo de Fabritiis, Gioia Colafigli, Pasquale Niscola, Salvatore Perrone, Robin Foà, Tapan M. Kadia and Elias Jabbour and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Matteo Molica

66 papers receiving 765 citations

Peers

Matteo Molica
Carla B. Ripamonti Italy
Abdulkadyrov Km Russia
Abelardo Bárez Spain
André Brizard France
Lauren E. Damon United States
P. Rae United States
Lucy J. Elrick United Kingdom
Michael Andreef United States
Ning‐ning Shan China
Bertil Uggla Sweden
Carla B. Ripamonti Italy
Matteo Molica
Citations per year, relative to Matteo Molica Matteo Molica (= 1×) peers Carla B. Ripamonti

Countries citing papers authored by Matteo Molica

Since Specialization
Citations

This map shows the geographic impact of Matteo Molica's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matteo Molica with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matteo Molica more than expected).

Fields of papers citing papers by Matteo Molica

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matteo Molica. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matteo Molica. The network helps show where Matteo Molica may publish in the future.

Co-authorship network of co-authors of Matteo Molica

This figure shows the co-authorship network connecting the top 25 collaborators of Matteo Molica. A scholar is included among the top collaborators of Matteo Molica based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matteo Molica. Matteo Molica is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Alati, Caterina, Matteo Molica, Gaetana Porto, et al.. (2025). CAR-T Cell Therapies in B-Cell Acute Lymphoblastic Leukemia: Emerging Data and Open Issues. Cancers. 17(18). 3027–3027. 2 indexed citations
3.
4.
Canichella, Martina, Matteo Molica, Carla Mazzone, & Paolo de Fabritiis. (2024). Maintenance Therapy Post-Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. Current Oncology. 31(10). 6050–6060. 1 indexed citations
5.
Molica, Matteo, Salvatore Perrone, Marco Rossi, & Diana Giannarelli. (2024). The impact of different FLT3-inhibitors on overall survival of de novo acute myeloid leukemia: A network meta-analysis. Leukemia Research. 144. 107549–107549. 1 indexed citations
6.
Molica, Matteo, Salvatore Perrone, & Marco Rossi. (2023). Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3-Mutated AML Patients. Journal of Clinical Medicine. 12(11). 3647–3647. 16 indexed citations
7.
Molica, Matteo, et al.. (2023). Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress. Cancers. 15(20). 5060–5060. 2 indexed citations
8.
9.
Molica, Matteo, Nélida I. Noguera, Malgorzata Monika Trawinska, et al.. (2020). Treatment-Free Remission in Chronic Myeloid Leukemia: Lights and Shadows. SHILAP Revista de lepidopterología. 12(11). 8950–8950. 3 indexed citations
10.
Carmosino, Ida, Massimo Breccia, Sara Mohamed, et al.. (2019). Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib. Oncology Research and Treatment. 42(12). 660–664. 3 indexed citations
11.
Molica, Matteo, Massimo Breccia, Roberto Foà, Elias Jabbour, & Tapan M. Kadia. (2019). Maintenance therapy in AML: The past, the present and the future. American Journal of Hematology. 94(11). 1254–1265. 58 indexed citations
12.
Latagliata, Roberto, Massimo Breccia, Ida Carmosino, et al.. (2018). Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?. European Journal Of Haematology. 101(5). 578–584. 1 indexed citations
13.
Molica, Matteo, Emilia Scalzulli, Gioia Colafigli, et al.. (2018). Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events. Annals of Hematology. 97(10). 1803–1808. 18 indexed citations
14.
Massaro, Fulvio, Matteo Molica, & Massimo Breccia. (2017). Ponatinib: A Review of Efficacy and Safety. Current Cancer Drug Targets. 18(9). 847–856. 62 indexed citations
15.
Breccia, Massimo, Caterina Stefanizzi, Sara Raponi, et al.. (2014). Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocitic leukemia cells. Annals of Hematology. 93(11). 1819–1823. 15 indexed citations
16.
17.
Molica, Stefano, Francesca Romana Mauro, Matteo Molica, Ilaria Del Giudice, & Robin Foà. (2012). Monoclonal B-cell lymphocytosis: a reappraisal of its clinical implications. Leukemia & lymphoma. 53(9). 1660–1665. 6 indexed citations
18.
Molica, Stefano, Giovanna Digiesi, Anna Antenucci, et al.. (2011). Vitamin D insufficiency predicts time to first treatment (TFT) in early chronic lymphocytic leukemia (CLL). Leukemia Research. 36(4). 443–447. 21 indexed citations
19.
Molica, Stefano, Giovanna Digiesi, C Battaglia, et al.. (2010). Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia. European Journal Of Haematology. 85(4). 314–320. 20 indexed citations
20.
Molica, Stefano, Giovanna Digiesi, Giovanna Cutrona, et al.. (2009). Serum level of CD26 predicts time to first treatment in early B‐chronic lymphocytic leukemia. European Journal Of Haematology. 83(3). 208–214. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carla B. Ripamonti Breakdown of academic impact, for papers by Abdulkadyrov Km Breakdown of academic impact, for papers by Abelardo Bárez Breakdown of academic impact, for papers by André Brizard Breakdown of academic impact, for papers by Lauren E. Damon Breakdown of academic impact, for papers by P. Rae Breakdown of academic impact, for papers by Lucy J. Elrick Breakdown of academic impact, for papers by Michael Andreef Breakdown of academic impact, for papers by Ning‐ning Shan Breakdown of academic impact, for papers by Bertil Uggla
Rankless by CCL
2026